These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 23331217)
1. Editors' note on special issue on medical product safety. Tsong Y; Chen J J Biopharm Stat; 2013; 23(1):1-2. PubMed ID: 23331217 [No Abstract] [Full Text] [Related]
2. FDA issues guidelines for biosimilar drugs. Cancer Discov; 2012 Mar; 2(3):196. PubMed ID: 22585973 [No Abstract] [Full Text] [Related]
3. Post-market drug safety evidence sources: an analysis of FDA drug safety communications. Ishiguro C; Hall M; Neyarapally GA; Dal Pan G Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257 [No Abstract] [Full Text] [Related]
4. What's best for the patient? Burkle WS Am J Hosp Pharm; 1983 Apr; 40(4):558. PubMed ID: 6846359 [No Abstract] [Full Text] [Related]
5. Compounding USP <797>: inspection, regulation, and oversight of sterile compounding pharmacies. Kastango ES JPEN J Parenter Enteral Nutr; 2012 Mar; 36(2 Suppl):38S-39S. PubMed ID: 22275322 [TBL] [Abstract][Full Text] [Related]
6. US drug shortages are set to reach record high in 2011, report says. Tanne JH BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406 [No Abstract] [Full Text] [Related]
7. [Drug safety: the obligation of information recognized in Washington]. Chneiweiss H Med Sci (Paris); 2009 Mar; 25(3):317. PubMed ID: 19361399 [No Abstract] [Full Text] [Related]
8. Adulteration of drugs and foods: compendial approaches to lowering risk. Abernethy DR; Sheehan C; Griffiths JC; Williams RL; Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621 [No Abstract] [Full Text] [Related]
9. LyphoMed sparks worries. Wagner M Mod Healthc; 1988 Jul; 18(29):5. PubMed ID: 10325202 [No Abstract] [Full Text] [Related]
10. Keeping up with drug safety information. Meadows M FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667 [No Abstract] [Full Text] [Related]
11. Distinguishing product and practice regulation in personalized medicine. Evans BJ Clin Pharmacol Ther; 2007 Feb; 81(2):288-93. PubMed ID: 17259953 [TBL] [Abstract][Full Text] [Related]
13. Regulating drugs for effectiveness and safety: a public health perspective. Zito JM; Socolar SJ; Eilers R; Crystal S; Lexchin J Med Care; 2007 Sep; 45(9):911. PubMed ID: 17712264 [No Abstract] [Full Text] [Related]
14. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint. Ley HL; Desmond FH Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100 [No Abstract] [Full Text] [Related]
15. Should herbal medicines be regulated as drugs? McGuffin M Clin Pharmacol Ther; 2008 Mar; 83(3):393-5. PubMed ID: 18285785 [No Abstract] [Full Text] [Related]
17. The FDA and the fight against terrorism. Meadows M FDA Consum; 2004; 38(1):20-7. PubMed ID: 15032200 [No Abstract] [Full Text] [Related]
18. Drug Product Problem Reporting Program. FDA Drug Bull; 1979 Aug; 9(3):18. PubMed ID: 467875 [No Abstract] [Full Text] [Related]
19. Drug safety: the viewpoint of the pharmaceutical manufacturing industry. Wigle WW Can Med Assoc J; 1968 Feb; 98(6):314-7. PubMed ID: 5636099 [No Abstract] [Full Text] [Related]